Author/Authors :
Basınoğlu, Filiz Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Kural, Alev Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Sağlam, Zuhal Aydan Haseki Training and Research Hospital - 4th Clinic of Internal Medicine Specialist of Family Practition, Turkey , Koldaş, Macit Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Döventaş, Yasemin E. Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Seval, Hatice Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Coşkun, Cihan Haseki Training and Research Hospital - Department of Biochemistry, Turkey , Öztürk, Hümeyra Haseki Training and Research Hospital - Department of Biochemistry, Turkey
Abstract :
Purpose: Fibronectin might play an important role in pathogenesis and progression of chronicdiabetic complications. The aim of this study is to estimate the plasma concentrations of fibronectin, AGEs (Advanced Glycosylation End Products), AOPPs (Advanced Oxidation Protein Products) T1DM (Type 1 Diabetes Mellitus) patients as well as the relationship between each other and diabetic complications. Material and Methods: Fourty T1DM patients attending to the Diabetes and Endocrinology outpatient clinic in Haseki Hospital and 17 healthy volunteers as control group were included in this study. AGEs and AOPPs were measured spectrophotometrically and fibronectin was measured with nephelometric method. Results: Fibronectin levels of diabetic patients were significantly higher than control group (p 0.05). There was not any significant difference in fibronectin levels between patients with and without diabetic complications. In addition, no statistically significant difference was observed in AGE and AOPP levels among diabetic patients and control group. No correlation was determined between plasma fibronectin and AGE and AOPP levels (r=0.4) either. Conclusion: No significant correlation was determined between fibronectin levels and AGE and AOPP which play an important role in progression of diabetic complications in T1DM. The lack of significant difference between healthy controls and patients with T1DM suggests that treatment counteracts the increase in free radical production.
